R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Oncology Account Manager

Field SalesConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A master's or bachelor's degree and 12–15+ years of biopharmaceutical industry experience are required.
  • At least 8–12+ years of prior oncology product sales experience is required.
  • A proven track record of product launch success in the oncology therapeutic space is required.
  • Oral oncolytic product launch experience is required.
  • Experience launching oncology products with companion diagnostics is required.
  • Proven performance in highly competitive marketplaces is required.
  • Proven performance in solo-representative selling environments is required.
  • Demonstrated success operating in small- to midsize-biotechnology environments is required.
  • Ability to meet territorial travel requirements and travel to meetings, training, and programs as necessary is required.
  • Effectiveness in highly collaborative and cross-functional working environments is required.
  • A valid driver's license is required.
  • Permanent residence in the accountable territory is required.
  • Approximately 50% travel is required.

Responsibilities

  • Market Revolution Medicines’ product portfolio effectively in the designated territory.
  • Exceed assigned territory performance goals by effectively positioning the benefits and use of the company’s products for appropriate patients.
  • Manage time effectively by directing effort toward engagements that drive brand value and prioritizing activities that positively affect patients.
  • Partner with key internal stakeholders to remove barriers to care and ensure every eligible patient receives timely access to the company’s products.
  • Adapt between virtual and in-person engagements and develop business plans that consider account communication preferences.
  • Analyze key market data and turn insights into effective business planning, implementing plans by engaging key targets through call optimization and resource utilization.
  • Develop deep, sustained customer relationships across assigned accounts and proactively challenge customers through innovative, value-driven solutions.
  • Represent the company’s brands professionally, compliantly, ethically, and effectively.
  • Maintain a thorough understanding of disease states, company products, and relevant competitor offerings, and articulate product value across digital, live, and other communication channels.
  • Maintain a comprehensive understanding of the reimbursement process and fulfillment pathways for oral oncolytics.
  • Manage the territory effectively and demonstrate strong selling competencies.
  • Creatively gain access to customers in the modern landscape.
  • Drive team effectiveness and shared-goal accomplishment by leveraging and sharing expertise and information.
  • Manage territory resources and budget effectively.
  • Comply with laws, regulations, and policies governing company staff conduct.
  • Embody corporate core values and cultivate an energized team culture focused on patient impact.

Desired Qualifications

  • Experience in the non-small cell lung cancer oncology space.
  • An advanced degree such as an MBA, PharmD, or PhD.
  • Strong organization, planning, project management, technical, and analytical skills.
  • Other relevant experience, such as sales operations, market research, or market access.
  • Ability to work independently to execute strategic and tactical plans under tight timelines.
  • Ability to deliver compelling presentations to individuals and groups, adapting messaging to maximize audience engagement.
  • High proficiency in Microsoft Office, including PowerPoint, Excel, and Word.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs